Imugene Limited (IMU) | BULLS N' BEARS

Imugene doses first patient in “hard to treat” cancer drug trial

Nov 11

Imugene doses first patient in “hard to treat” cancer drug trial

Fresh from news of a “complete response” from other clinical trials last week, Imugene (ASX: IMU) has now dosed the first patient with a...

Imugene launches first Aussie lymphoma cancer trial

Doug Bright

Nov 8

Imugene launches first Aussie lymphoma cancer trial

In an Australian first, clinical cancer researcher and developer Imugene (ASX: IMU) will launch its first “azer-cel” clinical trial...

Imugene hails 2-year “complete response” in cancer trial

Doug Bright

Nov 5

Imugene hails 2-year “complete response” in cancer trial

Clinical-stage immuno-oncology company Imugene (ASX: IMU) is celebrating more than two years’ “complete response” for one of its bile...

Imugene gets crucial FDA nod for bile tract cancer drug

Craig Nolan

Sep 18

Imugene gets crucial FDA nod for bile tract cancer drug

Imugene (ASX: IMU) has landed a prized United States Food and Drug Administration (FDA) orphan drug approval for its bile tract cancer...

Early trial results leave Imugene patients cancer-free

Andrew Todd

Sep 2

Early trial results leave Imugene patients cancer-free

The first two blood cancer patients taking part in a United States-based trial, who had suffered relapses despite having treatment, have...

Imugene delivers first Aussie bile tract cancer trial dose

Craig Nolan

Jul 10

Imugene delivers first Aussie bile tract cancer trial dose

Imugene (ASX: IMU) has dosed its first of 10 Australian patients with its potent “VAXINIA” therapy as part of its phase-one bile tract...

Imugene delivers first combo dose in bile tract cancer study

Doug Bright

Jun 24

Imugene delivers first combo dose in bile tract cancer study

Imugene (ASX: IMU) has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duct cancer patient in the...

Imugene cancer fight bolstered by strategic US partnership

Helen Barling

Apr 16

Imugene cancer fight bolstered by strategic US partnership

Australian anti-cancer company Imugene (ASX: IMU) has stamped a strategic manufacturing and processing agreement with Kincell Bio, with...

Imugene launches pivotal bile tract cancer expansion study

Steve Butler

Apr 15

Imugene launches pivotal bile tract cancer expansion study

ASX-listed medical technology company Imugene (ASX: IMU) has launched a pivotal expansion study targeting patients with bile tract...

Imugene locks down cancer patent in massive Chinese market

Michael Philipps

Apr 4

Imugene locks down cancer patent in massive Chinese market

Australian anti-cancer company Imugene (ASX: IMU) has received a patent to protect its unique cancer treatment in China – the largest and...

Imugene to tackle cancer tumours with combo treatment

Michael Philipps

Mar 11

Imugene to tackle cancer tumours with combo treatment

Imugene (ASX: IMU) has cleared the first hurdle in its clinical trial to test the safety and efficacy of its “onCARlytics” treatment for...

Imugene advances search-and-destroy cancer mission

Michael Philipps

Feb 15

Imugene advances search-and-destroy cancer mission

An Australian-based medical mission to flesh out and kill cancerous cells in humans has received a boost after ASX-listed medtech Imugene...

Imugene extends anti-cancer trial following recent successes

Doug Bright

Jan 19

Imugene extends anti-cancer trial following recent successes

Following recent successes, Imugene has advanced its Phase 1 clinical study with the first Cohort 5 patients now receiving doses of the...

Imugene to expand cancer treatment trial following early success

Doug Bright

Jan 17

Imugene to expand cancer treatment trial following early success

Clinical stage immune-oncology company Imugene has reported some eye-catching results in an update of its Phase 1 trial to assess the...

Imugene out to supercharge cancer patients in new alliance

Doug Bright

Dec 12, 2023

Imugene out to supercharge cancer patients in new alliance

Imugene has joined with United States-based NeoImmuneTech (NIT) for a two-year collaboration aimed at combining their respective...

Imugene on brink of European patent for cancer drug

Michael Philipps

Dec 6, 2023

Imugene on brink of European patent for cancer drug

Imugene expects to secure a crucial patent for its “PD1-Vaxx” lung cancer vaccine from the European Patent Office this month, with a...

Imugene cancer virus earns crucial FDA fast-track status

Doug Bright

Nov 28, 2023

Imugene cancer virus earns crucial FDA fast-track status

The US Food and Drug Administration has stamped Imugene’s “Vaxinia” drug trials aimed at treating bile duct cancer with “fast-track”...

Cancer-fighting mission shoots Imugene up ASX boards

Michael Philipps

Nov 13, 2023

Cancer-fighting mission shoots Imugene up ASX boards

Cancer. In modern days of fast vehicles and seemingly even faster living, there are few people or families who have not been touched by...

Holy grail cancer treatment one step closer for Imugene

Doug Bright

Nov 10, 2023

Holy grail cancer treatment one step closer for Imugene

Imugene has continued to set the ASX boards alight after revealing it had delivered the first dose of its azer-cel therapy to a patient...

Hope grows with positive signals in Imugene cancer trial

Helen Barling

Nov 6, 2023

Hope grows with positive signals in Imugene cancer trial

Australian immune-oncology company Imugene has recorded positive early signals from the first phase of its metastatic advanced solid...

BULLS N' BEARS HOLDINGS PTY LTD

ABN 61 606 991 824
ACN 606 991 824

Contact us